touchREVIEWS in Ophthalmology – Volume 15, Issue 2

Welcome to the latest edition of touchREVIEWS in Ophthalmology, which includes a wide range of articles that reflect the rapid pace and broad scope of ophthalmology research. Regrettably, we begin with an obituary. We are sorry to announce the death of one of our valued board members, Professor Emilio Campos. Starting from the front of the […]

We are sorry to announce the death of one of our valued board members, Professor Emilio Campos. Professor Campos was born in Trieste, Italy. His father had been professor of ophthalmology in Naples, but was forced by Mussolini’s anti-Jewish laws to flee to Geneva. Professor Campos trained in Modena, Italy with Professor Bruno Bagolini, with […]

Varicella zoster virus is a double-stranded DNA herpesvirus that resides dormant in the sensory nerve ganglia after primary infection of varicella/chicken pox. While primary infection can be mild, on reactivation, the virus typically causes a painful vesicular rash called herpes zoster (HZ), that affects approximately 1 million people per year in the USA.1 The incidence of […]

Keratoconus is the most common primary progressive ectatic condition of the cornea. It is classically described as non-inflammatory, distinguishing it from several other pathologies associated with corneal thinning. Prevalence of this disease varies depending on geographical location, with reports as high as 2.3% in Central India to 0.3% in Russia.1,2 Keratoconus typically presents as a bilateral […]

Continuous-wave transscleral laser cyclophotocoagulation (CW-TSCPC) is a well-established procedure in the surgical armamentarium of glaucoma management.1 It offers a non-incisional option in the treatment of end-stage refractory glaucoma, in which fistulating surgery and maximum tolerated medical therapy have failed to achieve a target intraocular pressure (IOP).2 CW-TSCPC is typically delivered using the G-Probe® (IRIDEX Corporation, Mountain View, […]

The development of anti-vascular endothelial growth factor (VEGF) agents as intravitreal treatments for neovascular age-related macular degeneration (nAMD) has drastically improved the vision outcomes for this disorder. Ranibizumab, a recombinant, humanized monoclonal antibody that targets VEGF-A, was approved in 2006 by the US Food and Drug Administration (FDA) for the treatment of nAMD. The pivotal […]

Dry eye disease (DED) is an inflammatory condition of the cornea and conjunctiva that is characterized by tear-film instability and increased tear osmolarity.1–3 While DED is traditionally viewed as a chronic condition, many patients experience episodic exacerbations of the disease, also referred to as flares or episodic dry eye.1 Until recently, the need for an effective treatment […]